What is CDT's P/E ratio?

Conduit Pharmaceuticals Inc. (CDT) currently trades at a P/E ratio of 0.02.

Conduit Pharmaceuticals Inc. reports a Return on Equity (ROE) of 6.58%.

What is CDT's dividend yield?

Conduit Pharmaceuticals Inc. offers a dividend yield of 0.00%.

What is CDT's Quality Score?

Our AI rates CDT's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CDT?

Our AI Timing Score for CDT is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CDT belong to?

Conduit Pharmaceuticals Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Conduit Pharmaceuticals Inc. (CDT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-06-30)

CDT AI Analysis Summary

Our AI summary for CDT: Conduit Pharmaceuticals Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.02, ROE of 6.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CDT

Conduit Pharmaceuticals Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 3.59

0.45 (14.33%) Day Change

Watchlist Portfolio Compare Chart

0.02

P/E

1.53

D/E

6.6%

ROE

2.6%

ROA

0.00%

Div Yield

CONDUIT PHARMACEUTICALS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.59 Price 0.45 (14.33%) Day Change	NEWS SCORE: 98

CDT, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.59
PBV / Sector	N/A / 44,105.10
Earning Per Share	165.08

PE / Sector	0.02 / 19.37 GREAT
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.23 M GREAT
Average 1W Daily Value	0.35 M GREAT

Timing Factors

100%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	1.87 / 97.23
NPM Average (%) / Sector	-0.50 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	2.60 / 185,260.64
ROA Average (%) / Sector	-19,634.10 / 36,684.64
ROA Change Average (%) / Sector	1,274.54 / 422,221.42
ROE (%) / Sector	6.58 / 243,761.81
ROE Average (%) / Sector	86.21 / 48,758.38 GREAT
ROE Change Average (%) / Sector	-36.95 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:46
Symbol	CDT
Name	CONDUIT PHARMACEUTICALS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	0.63 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1.98 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4581 Tamiami Trail North, Naples, FL, United States, 34103

Phone: 646 491 9132

Website: https://www.cdtequity.com

Sector: Healthcare >> Biotechnology

Description: CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.